Confronto
Degarelix vs. Epitalon
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
214766-78-6
307297-39-8
Peso molecolare
1632.3 g/mol
390.35 g/mol
Emivita
1320 h
0.3 h
Sequenza
Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph(Hor)-D-4Aph(Cbm)-Leu-Ilys-Pro-D-Ala-NH2Ala-Glu-Asp-GlyMeccanismo d'azione
Degarelix
Degarelix is a competitive GnRH receptor antagonist. It binds reversibly and immediately to the pituitary GnRH receptors and blocks their activation. This rapidly suppresses the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn lowers testosterone production in the testes. Unlike GnRH agonists (e.g., leuprorelin), which first cause a transient stimulation with a testosterone surge (flare), this direct antagonism lacks the initial stimulation phase, so testosterone declines without a preceding rise. This mechanism underlies the literature-described use in hormone-dependent prostate cancer.
Epitalon
Postulated mechanisms include modulation of gene expression in pinealocytes, telomerase activation (observed in cell culture studies) and influence on melatonin synthesis. A defined primary receptor is not established; the mechanistic basis rests on in-vitro and animal data from the Khavinson group.
Base di evidenze
Evidenza più alta
RCT sull'uomo
Studio sull'uomo
Studi
4
4
di cui sull'uomo
4
1
Effetti registrati
4
4
Contraddizioni aperte
1
1
Eventi avversi documentati
2
1
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Degarelix and Epitalon?
- Degarelix is classified as "Ricerca (altro)", while Epitalon is classified as "Ricerca (altro)". Degarelix: Degarelix (trade name Firmagon) is a synthetic decapeptide and a gonadotropin-releasing hormone (GnRH) receptor antagonist. Unlike GnRH agonists, it blocks the receptor directly and does not trigger an initial testosterone surge (flare). It is an approved prescription medicine for the treatment of advanced, hormone-dependent prostate cancer. This page neutrally summarizes the evidence base and legal status and is not a usage or dosing recommendation. Epitalon: Synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from the pineal extract epithalamin (V. Khavinson, St. Petersburg). Investigated in the Russian research and anti-ageing context; Western controlled trials are largely absent. No medicines approval in EU or US. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Degarelix or Epitalon?
- The highest available evidence level is "RCT sull'uomo" for Degarelix and "Studio sull'uomo" for Epitalon. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Degarelix and Epitalon in Germany and the United States?
- Germania: Degarelix — Su prescrizione, Epitalon — Non approvato. Stati Uniti: Degarelix — Su prescrizione, Epitalon — Non approvato. These are factual summaries with source and review date on the individual pages.